Therapy Area topics
Cardiovascular
Novo seeks a cardiovascular boost
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Central Nervous System
Quanterix sees a bright future for blood biomarkers
A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Diabetes
Novo seeks a cardiovascular boost
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Digital Health
Sofinnova goes digital
The promise of fast timelines and early revenues lure a new investor into digital medicine.
ESC 2022 – Preventicus gets halfway there
Improving atrial fibrillation diagnosis is one thing; improving outcomes another.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Oncology
Asco 2023 – Enhertu hits with pan approach
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Asco 2023 – Bicara eyes head and neck niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
Respiratory
Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Sanofi seeks to build on COPD win
Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.
Various
Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
